journal article·2020-04

An in vitro hyaluronic acid hydrogel based platform to model dormancy in brain metastatic breast cancer cells

Akshay A. Narkhede, James H. Crenshaw, David K. Crossman, Lalita A. Shevde, Shreyas S. Rao

Acta Biomaterialia· Volume 107
Publisher page

Abstract

Breast cancer cells (BCCs) can remain dormant at the metastatic site, which when revoked leads to formation of metastasis several years after the treatment of primary tumor. Particularly, awakening of dormant BCCs in the brain results in breast cancer brain metastasis (BCBrM) which marks the most advanced stage of the disease with a median survival period of ~4-16 months. However, our understanding of dormancy associated with BCBrM remains obscure, in part, due to the lack of relevant in vitro platforms to model dormancy associated with BCBrM. To address this need, we developed an in vitro hyaluronic acid (HA) hydrogel platform to model dormancy in brain metastatic BCCs via exploiting the bio-physical cues provided by HA hydrogels while bracketing the normal brain and metastatic brain malignancy relevant stiffness range. In this system, we observed that MDA-MB-231Br and BT474Br3 brain metastatic BCCs exhibited a dormant phenotype when cultured on soft (0.4 kPa) HA hydrogel compared to stiff (4.5 kPa) HA hydrogel as characterized by significantly lower EdU and Ki67 positivity. Further, we demonstrated the nuclear localization of p21 and p27 (markers associated with dormancy) in dormant MDA-MB-231Br cells contrary to their cytoplasmic localization in the proliferative population. We also demonstrated that the stiffness-based dormancy in MDA-MB-231Br cells was reversible and was, in part, mediated by focal adhesion kinases and the initial cell seeding density. Finally, RNA sequencing confirmed the dormant phenotype in MDA-MB-231Br cells. This platform could further our understanding of dormancy in BCBrM and could be adapted for anti-metastatic drug screening. STATEMENT OF SIGNIFICANCE: Our understanding of dormancy associated with BCBrM remains obscure, in part, due to the lack of relevant in vitro platforms to model dormancy associated with BCBrM. Herein, we present a HA hydrogel-based platform to model dormancy in brain metastatic BCCs while recapitulating key aspects of brain microenvironment. We demonstrated that the biophysical cues provided the HA hydrogel mediates dormancy in brain metastatic BCCs by assessing both proliferation and cell cycle arrest markers. We also established the role of focal adhesion kinases and initial cell seeding density in the stiffness-mediated dormancy in brain metastatic BCCs. Further, RNA-seq. confirmed the dormant phenotype in brain metastatic BCCs. This platform could be utilized to further our understanding of microenvironmental regulation of dormancy in BCBrM.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Cancer Cells and Metastasis · Proteoglycans and glycosaminoglycans research · Mesenchymal stem cell research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (76)

Show source-provided references
1. Biomimetic strategies to recapitulate organ specific microenvironments for studying breast cancer metastasis10.1002/ijc.30748 ↗
2. Bioengineered models to study tumor dormancy10.1186/s13036-018-0137-0 ↗
3. Metastasis awakening: targeting dormant cancer10.1038/nm.3120 ↗
4. Framework models of tumor dormancy from patient-derived observations10.1016/j.gde.2010.10.011 ↗
5. Engineered in vitro models of tumor dormancy and reactivation10.1186/s13036-018-0120-9 ↗
6. Mechanisms of disseminated cancer cell dormancy: an awakening field10.1038/nrc3793 ↗
7. The influence of matrix stiffness on the behavior of brain metastatic breast cancer cells in a biomimetic hyaluronic acid hydrogel platform10.1002/jbm.a.36379 ↗
8. Breast cancer brain metastases: biology and new clinical perspectives10.1186/s13058-015-0665-1 ↗
9. Dormancy in cancer10.1111/cas.13917 ↗
10. Tunable hydrogels for controlling phenotypic cancer cell states to model breast cancer dormancy and reactivation10.1016/j.biomaterials.2019.04.022 ↗
11. Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton10.1158/0008-5472.CAN-07-6849 ↗
12. An in vitro system to study tumor dormancy and the switch to metastatic growth
13. Combined SFK/MEK inhibition prevents metastatic outgrowth of dormant tumor cells10.1172/JCI70259 ↗
14. Metastatic growth from dormant cells induced by a col-I-enriched fibrotic environment10.1158/0008-5472.CAN-09-2356 ↗
15. Investigating breast cancer cell behavior using tissue engineering scaffolds10.1371/journal.pone.0118724 ↗
16. The perivascular niche regulates breast Tumour dormancy10.1038/ncb2767 ↗
17. From competency to dormancy: a 3D model to study cancer cells and drug responsiveness10.1186/s12967-016-0798-8 ↗
18. Fibrin stiffness mediates dormancy of tumor-repopulating cells via a CDC42-driven TET2 epigenetic program10.1158/0008-5472.CAN-17-3719 ↗
19. Low levels of sox2 are required for melanoma tumor-repopulating cell dormancy10.7150/thno.29698 ↗
20. Chemomechanically engineered 3D organotypic platforms of bladder cancer dormancy and reactivation10.1016/j.biomaterials.2017.07.008 ↗
21. A novel model of dormancy for bone metastatic breast cancer cells10.1158/0008-5472.CAN-13-0991 ↗
22. Identification of genes regulating breast cancer dormancy in 3D bone endosteal niche cultures10.1158/1541-7786.MCR-18-0956 ↗
23. Dormancy and growth of metastatic breast cancer cells in a bone-like microenvironment10.1007/s10585-015-9710-9 ↗
24. Spontaneous dormancy of metastatic breast cancer cells in an all human liver microphysiologic system10.1038/bjc.2014.533 ↗
25. Hepatic nonparenchymal cells drive metastatic breast cancer outgrowth and partial epithelial to mesenchymal transition10.1007/s10549-014-2875-0 ↗
26. A liver microphysiological system of tumor cell dormancy and inflammatory responsiveness is affected by scaffold properties10.1039/C6LC01171C ↗
27. Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy
28. In vivo MRI of cancer cell fate at the single-cell level in a mouse model of breast cancer metastasis to the brain10.1002/mrm.21029 ↗
29. Hyaluronan expression in primary and secondary brain tumors
30. Hyaluronic acid: incorporating the bio into the material10.1021/acsbiomaterials.8b01268 ↗
31. Elucidating the mechanobiology of malignant brain tumors using a brain matrix-mimetic hyaluronic acid hydrogel platform10.1016/j.biomaterials.2011.07.005 ↗
32. Inhibition of type i insulin-like growth factor receptor signaling attenuates the development of breast cancer brain metastasis10.1371/journal.pone.0073406 ↗
33. Cell-Cycle regulation accounts for variability in ki-67 expression levels10.1158/0008-5472.CAN-16-0707 ↗
34. Dormancy of solitary metastatic cells10.4161/cc.5.16.2864 ↗
35. STAR: ultrafast universal RNA-seq aligner10.1093/bioinformatics/bts635 ↗
36. HTSeq-a python framework to work with high-throughput sequencing data10.1093/bioinformatics/btu638 ↗
37. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq210.1186/s13059-014-0550-8 ↗
38. ClustVis: a web tool for visualizing clustering of multivariate data using principal component analysis and heatmap10.1093/nar/gkv468 ↗
39. A model of dormant-emergent metastatic breast cancer progression enabling exploration of biomarker signatures10.1074/mcp.RA117.000370 ↗
40. Inhibition of fak signaling activated by urokinase receptor induces dormancy in human carcinoma cells in vivo10.1038/sj.onc.1205342 ↗
41. S. Prekovic, K. Schuurman, A.G. Manjón, M. Buijs, I.M. Peralta, M.D. Wellenstein, S. Yavuz, A. Barrera, K. Monkhorst, A. Huber, B. Morris, C. Lieftink, J. Silva, B. Győrffy, L. Hoekman, B. van den Broek, H. Teunissen, T. Reddy, W. Faller, R. Beijersbergen, J. Jonkers, M. Altelaar, K.E. de Visser, E. de Wit, R. Medema, W. Zwart, Glucocorticoids regulate cancer cell dormancy, bioRxiv (2019) 750406, doi:https://doi.org/10.1101/750406.10.1101/750406 ↗
42. Expression profile of the N-myc downstream regulated gene 2 (NDRG2) in human cancers with focus on breast cancer10.1186/1471-2407-11-14 ↗
43. NDRG2 positively regulates E-cadherin expression and prolongs overall survival in colon cancer patients10.3892/or.2013.2642 ↗
44. Biomarkers for epithelial-mesenchymal transitions10.1172/JCI36183 ↗
45. Glioblastoma behaviors in three-dimensional collagen-hyaluronan composite hydrogels10.1021/am402097j ↗
46. Exploring the biomechanical properties of brain malignancies and their pathologic determinants in vivo with magnetic resonance elastography10.1158/0008-5472.CAN-14-1997 ↗
47. Three-dimensional culture models of normal and malignant breast epithelial cells10.1038/nmeth1015 ↗
48. Hyaluronan arrests human breast cancer cell growth by prolonging the G0/G1 phase of the cell cycle10.1093/abbs/gmy126 ↗
49. Cancer cell dormancy: mechanisms and implications of cancer recurrence and metastasis10.2147/OTT.S140854 ↗
50. Cytoplasmic translocation of p21 mediates NUPR1-induced chemoresistance: NUPR1 and p21 in chemoresistance10.1016/j.febslet.2012.07.063 ↗
51. Apoptosis inhibitory activity of cytoplasmic p21Cip1/WAF1 in monocytic differentiation10.1093/emboj/18.5.1223 ↗
52. Are p27 and p21 cytoplasmic oncoproteins?10.4161/cc.1.6.262 ↗
53. Inhibition of cyclin-dependent kinases by p2110.1091/mbc.6.4.387 ↗
54. Cdk-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase delta holoenzyme10.1073/pnas.91.18.8655 ↗
55. Negative regulation of ASK1 by p21Cip1 involves a small domain that includes serine 98 that is phosphorylated by ASK1 in vivo10.1128/MCB.00086-06 ↗
56. 3D Microenvironment stiffness regulates tumor spheroid growth and mechanics via p21 and Rock
57. Cell cycle progression in confining microenvironments is regulated by a growth-responsive TRPV4-PI3K/Akt-p27Kip1 signaling axis10.1126/sciadv.aaw6171 ↗
58. Matrix stiffness modulates proliferation, chemotherapeutic response, and dormancy in hepatocellular carcinoma cells10.1002/hep.24108 ↗
59. Cell density overrides the effect of substrate stiffness on human mesenchymal stem cells' morphology and proliferation10.1039/C7BM00853H ↗
60. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis10.1016/j.cell.2014.07.013 ↗
61. Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer10.1200/JCO.2010.33.3716 ↗
62. Intratumor heterogeneity and circulating tumor cell clusters10.1093/molbev/msy115 ↗
63. Investigating circulating tumor cells and distant metastases in patient-derived orthotopic xenograft models of triple-negative breast cancer10.1186/s13058-019-1182-4 ↗
64. In vitro model-systems to understand the biology and clinical significance of circulating tumor cell clusters10.3389/fonc.2018.00063 ↗
65. E-cadherin as an indicator of mesenchymal to epithelial reverting transitions during the metastatic seeding of disseminated carcinomas10.1007/s10585-008-9167-1 ↗
66. Down-regulation of epithelial cadherin is required to initiate metastatic outgrowth of breast cancer10.1091/mbc.e11-04-0306 ↗
67. The pan-therapeutic resistance of disseminated tumor cells: role of phenotypic plasticity and the metastatic microenvironment
68. Cancer cells enter dormancy after cannibalizing mesenchymal stem/stromal cells (MSCs)10.1073/pnas.1612290113 ↗
69. The senescence-associated secretory phenotype: the dark side of tumor suppression10.1146/annurev-pathol-121808-102144 ↗
70. Inside and out: the activities of senescence in cancer10.1038/nrc3773 ↗
71. Dormancy signatures and metastasis in estrogen receptor positive and negative breast cancer10.1371/journal.pone.0035569 ↗
72. NR2F1 controls tumour cell dormancy via SOX9- and RARβ-driven quiescence programmes10.1038/ncomms7170 ↗
73. Senescence in premalignant tumours10.1038/436642a ↗
74. Molecular mechanisms and emerging therapeutic targets of triple-negative breast cancer metastasis10.3389/fonc.2018.00031 ↗
75. The relationship between dormant cancer cells and their microenvironment10.1016/bs.acr.2016.07.002 ↗
76. Evaluation of proliferation and apoptosis markers in circulating tumor cells of women with early breast cancer who are candidates for tumor dormancy10.1186/s13058-014-0485-8 ↗